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Summary To investigate the long-term survival rate of node-positive (pN+) breast cancer treated by locoregional therapy alone, we made an
attempt to identify all such patients followed up for at least 15 years after treatment in a defined geographical area (city of Turku,
Southwestern Finland) and time period (1945-79) using the files of the local hospitals and the Finnish Cancer Registry. The clinical and
autopsy records and histological slides of 1172 women diagnosed with breast cancer in the city were reviewed. From this cohort we identified
339 women with unilateral node-positive breast cancer treated with locoregional therapy without systemic adjuvant therapy. The relative
survival rate of the cohort compared with the general female population matched for age and year of follow-up was calculated. The 15- and
30-year survival rates corrected for known intercurrent deaths were 26% (95% Cl, 21-31%) and 21% (16-26%) respectively, and the relative
survival rates 23% and 21% respectively. None of the patients with pN2 disease survived for 15 years, whereas the 30-year corrected survival
rate in pN1 disease was 24% (18-30%). Women with pTl N1MO cancer had as high as 59% (43-75%) 15-year survival rate corrected for
intercurrent deaths. A trend for improving survival was found by the decade of diagnosis. The results indicate that a considerable proportion
of women with pNl breast carcinoma treated with locoregional therapy alone become 30-year survivors and are probably cured. Adequate
locoregional treatment is mandatory in the care of node-positive breast cancer.
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Presence of axillary nodal metastases and the number of involved
lymph nodes at diagnosis are well-established prognostic factors
in breast cancer. The management of the axilla in early breast
cancer is controversial (Sacks and Baum, 1993). Axillary nodal
dissection may cause morbidity, including post-operative seroma,
upper-limb numbness, pain, restriction of shoulder movement and
swelling of the arm. The need to perform axillary nodal dissection
for assessment of prognosis has been questioned because valid
prognostic information can be obtained by analysing clinical and
biological factors ofthe primary tumour, by detecting micrometas-
tases in the bone marrow (Harbeck et al, 1994) or by using the
sentinel node biopsy technique (Giuliano et al, 1995). Moreover,
two large randomized trials have suggested that failure to treat
involved axillary nodes is not associated with worse survival
(Cancer Research Campaign Working Party, 1980; Fisher et al,
1985), which has led to the hypothesis that metastatic axillary
nodes are an expression rather than a determinant of a poor
outcome. However, the results of two recently published random-
ized trials with a median follow-up of9.5 and 12.5 years show that
locoregional radiotherapy combined with adjuvant chemotherapy
is superior to adjuvant chemotherapy alone in premenopausal
node-positive patients treated with mastectomy (Overgaard et al,
1997; Ragaz et al, 1997), suggesting that careful treatment ofaxil-
lary nodal metastases is ofgreat importance in the management of
breast cancer.
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There are a few reported series in which a subset ofpatients with
node-positive breast cancer has been found to survive longer than
20 years after the diagnosis, suggesting that node-positive breast
cancer may sometimes be a curable disease (Adair et al, 1974;
Fentiman et al, 1984; Rutqvist et al, 1985; Rosen et al, 1989; Lee et
al, 1992; Nab et al, 1994). However, treatment given in these series
has been variable, and the series may have included patients who
received systemic treatments in addition to local therapy. Some of
the studies are based on single-centre data, raising the possibility of
patient selection. A systematic review ofthe histopathological data
particularly concerning axillary nodal involvement by cancer may
not have been performed, and often patients with a second primary
breast cancer have been included in the analyses. Moreover, there
are few data available on how to predict which patients, ifany, with
node-positive breast cancer might become long-term survivors.
Hence, the long-term survival rate of patients with node-positive
breast cancer treated with locoregional therapy only is difficult to
assess based on the studies available, and there is uncertainty as to
whether axillary nodal involvement by breast cancer should be
considered as a conclusive sign ofdisseminated disease or not.
In the present study we have followed up practically all women
with node-positive unilateral breast cancer diagnosed in a well-
defined geographical area for a minimum of 15 years after diag-
nosis. All patients were treated with mastectomy and axillary
nodal dissection without any adjuvant systemic therapy, and in all
cases the diagnosis and axillary lymph node involvement was
confirmed histologically. The results are compatible with the
hypothesis that the presence of axillary nodal metastases at the
time of the diagnosis is not a conclusive sign of disseminated
breast cancer, and that such patients can sometimes be cured by
locoregional therapy alone.
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PATIENTS AND METHODS
Patients
In order to identify all patients diagnosed with invasive breast
cancer in the city of Turku, located in Southwestern Finland, the
hospital records of the two hospitals in the city, the Turku
University Central Hospital and the City Hospital of Turku, were
examined. In addition, we searched the data obtained from the
Finnish Cancer Registry, founded in 1952. Hospitals, practising
physicians and pathological and haematological laboratories are
requested to report all cases of cancer that come to their attention
to the Finnish Cancer Registry. In addition, all death certificates in
which cancer is mentioned are transferred from the files of the
Statistics Finland to the Cancer Registry each year. After identi-
fying the patients from these sources, we reviewed the hospital and
autopsy case records and examined the histological and autopsy
slides. We identified and confirmed the diagnosis of invasive
breast cancer in 1172 female patients during the time period from
1945 to 1979. Based on the data obtained from the Finnish Cancer
Registry and the local hospital files, we estimate that this is at least
94% ofall cases diagnosed with breast cancer in the city during the
time period. The time period 1945-79 was chosen because this
would allow a minimum of 15-year follow-up for the patients still
alive. According to a previous analysis performed by us (Joensuu
and Toikkanen, 1995) and others (Hibberd et al, 1983; Nab et al,
1994), few women with unilateral breast cancer die of the disease
after the 15th year of follow-up.
The hospital and autopsy records, registry data and all histo-
logical material available on the 1172 patients were reviewed.
After this, women with ductal cancer in situ (n = 37), those with
distant metastases at presentation (n = 75) and those treated with a
palliative intent only (n = 31) were excluded, as well as women
who had synchronous or metachronous bilateral breast cancer (n =
72). From the remaining 957 patients we excluded all cases with
node-negative disease (pNO, n = 450) and those who did not have
axillary nodal dissection (n = 118). Fifty (12.9%) ofthe remaining
389 patients with unilateral, invasive, histopathologically node-
positive breast cancer treated with a curative intent had received
some kind of systemic therapy (ovarian ablation, n = 41; tamox-
ifen or cytostatic drugs, n = 9). The 339 remaining patients who
did not receive systemic adjuvant therapy form the basis of the
study. All 339 patients have been followed up for at least 15 years
or until death (median, 23 years; maximum, 41 years).
The median age at diagnosis was 56 years (range, 24-93).
Clinical staging was performed according to the International
Union Against Cancer tumour-node-metastasis (UICC TNM)
classification (1992).
Therapy
The majority (76%) of the patients were treated with radical or
modified radical mastectomy, and the rest with simple mastectomy
combined with axillary nodal dissection. At least level I and II
axillary nodes were usually removed. Most of the patients (84%)
received post-operative locoregional radiotherapy, either with
orthovoltage during the early study period (before 1973), or mega-
voltage irradiation in the 1970s. The ipsilateral axillary, supra-
clavicular, infraclavicular and parastemal nodes were usually
irradiated. The chest wall has been systematically irradiated
since 1973.
Histology
The original histological slides were reviewed by one pathologist
very experienced in breast cancer pathology (ST). New haema-
toxylin and eosin (H&E-) stained slides were prepared, if neces-
sary. Histological typing was performed according to the WHO
classification (1981), and the tumours were classified into the
following three types: (1) infiltrating ductal carcinoma not other-
wise specified (NOS; includes apocrine, mixed mucinous and
atypical medullary types); (2) infiltrating lobular carcinoma with
variants; and (3) other special types (includes tubular, medullary,
cribriform, papillary and pure mucinous carcinomas). Grading was
performed according to the WHO classification, and the grading of
infiltrating lobular cancer was done by evaluating the degree of
nuclear pleomorphism. The number of mitoses per high-power
field (Leizt Orthoplan microscope, x 400 magnification) was
counted as an average often fields.
In all 339 cases, the presence ofbreast cancer in axillary lymph
nodes was confirmed histopathologically. Cases in which cancer
was present outside the lymph node capsule were classified as
pN2. There were no pN3 cases in the series because the parasternal
lymph nodes were not removed at surgery. Supraclavicular
metastatic lymph nodes were classified as Ml disease (UICC
TNM classification, Hermanek and Sobin 1992). The number of
lymph nodes involved could not be reliably extracted from the
case records because the entire axillary content was not systemati-
cally investigated during the time period ofthe study.
Statistical methods
Statistical analyses were carried out with the BMDP computer
program (BMDP Statistical Software, Department of
Biomathematics, University of California, Los Angeles, CA,
USA). Frequency tables were analysed with the chi-square test.
The cumulative survival was estimated with the product-limit
method and comparison of the cumulative survival rate between
groups was performed with the log-rank test. Both overall (crude)
survival rate and survival rate corrected for intercurrent deaths
were calculated. When calculating the corrected survival rate,
patients who died from causes other than breast cancer according
to autopsy or clinical evidence were censored at the date of death.
A patient was considered to have died from cancer if distant
metastases confirmed by histology, cytology or imaging examina-
tions were present at the time of her death. The relative survival
rate was calculated by dividing the crude survival rate by the
expected rate in the general female population, matched for age
and year of observation. The expected survival rate was obtained
from the tables of Statistics Finland and the Finnish Cancer
Registry. The relative importance of prognostic factors was
analysed with Cox's proportional hazard model (BMDP 2L). All
P-values are two-tailed.
RESULTS
During the follow-up 236 (70%) ofthe 339 patients died of breast
cancer, 54 (16%) ofan intercurrent cause, ten (3%) ofcancer other
than breast cancer and in one case the cause of death could not be
determined. Thirty-eight (11%) women were still alive at the end
of follow-up. The last death caused by breast cancer in the series
took place 291 months (24 years) after the diagnosis, when 23
patients were still at risk. The 15-year and 30-year survival rates
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Figure 1 Overall survival, expected survival, relative survival and survival
corrected for intercurrent deaths among 339 women with node-positive
breast cancer treated with mastectomy, axillary nodal dissection and
locoregional radiotherapy. Survival figures at 10 and 25 years of follow-up
are shown
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Figure 2 Survival corrected for intercurrent deaths by post-surgical axillary
nodal status. The patients still alive (n = 38) are shown by bars. The survival
figures at 5, 10, 15 and 30 years of follow-up are shown
corrected for intercurrent deaths were 26% (95% confidence
interval, 21-31%) and 21% (16-26%) respectively.
The relative survival obtained by dividing the overall survival
rate by the expected survival rate in age-, sex- and year ofobserva-
tion-matched population resulted in a similar long-term survival
estimate that was obtained by correcting for known intercurrent
deaths by the clinical and autopsy data (Figure 1). The relative
survival rate remained essentially the same after the first 15 years
of follow-up with 21-23% of the patients remaining as long-term
survivors (Table 1).
None of the 35 patients with pN2 disease survived for 15 years
after the diagnosis, whereas 19% (15-23%) of patients with pNl
cancer were alive 15 years after the diagnosis and 9% (5-13%) 30
years after the diagnosis (P < 0.0001). When survival corrected for
intercurrent diseases was analysed, it turned out that 29% (23-35%)
of the patients with pN1 disease were 15-year survivors and 24%
(18-30%) were estimated to be 30-year survivors (Figure 2).
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Figure 3 Survival corrected for intercurrent deaths by post-surgical primary
tumour size (n = 333). The patients still alive (n = 37) are shown by bars. The
survival figures at 10 and 30 years of follow-up are shown
Table 1 Overall, corrected, expected and relative survival rates of 339
women with pN+ breast cancer treated with locoregional therapy alone
Years from Overall Survival Expected Relative
diagnosis survival corrected for survivalb survivalc
(%) intercurrent (%) (%)
causesa (%)
5 40 46 92 44
10 26 33 82 32
15 17 26 73 23
20 14 24 64 22
25 11 21 53 21
30 8 21 40 21
aDeaths due to causes other than breast cancer were censored. The cause
of death was determined based on clinical and autopsy data. bExpected
survival of female population matched for age and year of observation.
cOverall survival divided by expected survival.
The 15-year survival rate corrected for intercurrent deaths was
57% (42-72%) among patients with pTINlMO (n = 43) or
pTlN2MO (n = 3) disease and 59% (43-75%) among the43 patients
with pTINIMO disease (Figure 3). Histological grade, the number
of mitoses, presence of tumour necrosis, primary tumour size,
axillary nodal status (pN2 vs pNl) and histological type were also
significantly associated with corrected survival in a univariate
analysis (Table 2). When these six factors classified as in Table 2
were entered into a multivariate analysis, only histological grade
(relative risk 1.7; 95% confidence interval, 1.4-2.1), primary
tumour size (1.8, 1.5-2.2) and axillary nodal status (2.0, 1.4-3.0)
had independent influence on corrected oroverall survival (Table 3).
When the series was divided into three cohorts based on the
decade when the diagnosis was made, it turned out that survival
rates were better in the 1960s and 1970s than in the 1940s and
1950s (P < 0.0001). The 15-year corrected survival rate found
among women with pN+ disease diagnosed in the 1970s was 34%
(25-43%) compared with 13% (6-20%) in the 1940s and 1950s
(Table 4). The result remained essentially similar, if patients with
pN2 disease were excluded from the analysis (P < 0.0001).
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Table 2 Prognostic factors in a univariate analysis
Factor n Corrected survival P
5-year 10-year 20-year 30-year
(%) (%) (%) (%)
Histological grade
of differentiation
Well 52 86 65 46 46
Moderately 143 52 37 26 22
Poorly 144 26 19 15 13 < 0.0001
Mitotic count/HPFa
< 2 107 74 54 35 32
2-3 133 37 26 22 18
> 3 99 27 21 17 14 < 0.0001
Presence of necrosis
No 213 57 41 29 26
Yes 126 28 21 16 14 < 0.0001
Tumour size
<2cm 46 73 63 57 57
2-5 cm 169 50 35 24 22
> 5 cm or pT4 118 28 17 12 10 < 0.0001
Axillary nodal status
pNl 304 49 36 27 24
pN2 35 17 7 0 0 < 0.0001
Histological type
Ductal 291 42 31 22 19
Lobular 35 58 33 28 21
Special 13 100 89 67 67 0.006
Age at diagnosis
<56 (median) 171 39 26 23 20
> 56 168 53 42 24 - 0.09
aHPF, high-power field.
DISCUSSION
In the present series a considerable proportion of breast cancer
patients with histologically confirmed axillary nodal metastases at
diagnosis were long-term survivors even if no systemic treatment
was given. The series includes the great majority ofpatients diag-
nosed in a well-defined urban area, which precludes a major selec-
tion bias. Only a few deaths from ipsilateral breast cancer take
place after the 15th year of follow-up in node-positive or node-
negative disease (Hibberd et al, 1983; Nab et al, 1994; Joensuu
and Toikkanen, 1995), and, therefore, it is unlikely that a longer
follow-up would have changed the result ofthe study markedly.
These data suggest that involvement ofthe axillary lymph nodes
by cancer is not a conclusive sign of disseminated disease.
Hypothetically, the patients who survive fordecades after the diag-
nosis ofbreast cancer metastatic to the axillary lymph nodes might
have dormant cancer cells and die from intercurrent diseases
before they succumb to breast cancer. However, we observed no
deaths from ipsilateral breast cancer after the 24th year of follow-
up, and the relative survival was the same as that found in the
general population after the 15th year of follow-up. Therefore,
locoregional therapy is likely to be curative in a subset ofpatients
with node-positive breast cancer.
It is worth noting that patients with a small primary tumour
(pTIN1MO) had as favourable as 59% 15-year survival rate
corrected for intercurrent deaths. This figure is in line with that
found by Rosen et al (1989), who estimated that 52% of patients
Table 3 Multivariate survival analyses
Factor P J Standard Relative risk
error of (95% confidence
interval)
Overall survival
Histological grade <0.001 0.40 0.08 1.5 (1.3-1.8)
(G3vsG2vsGl)
Primary tumour size < 0.001 0.39 0.09 1.5 (1.2-1.8)
(pT3-4 vs pT2 vs pTl)
Axillary nodal status < 0.001 0.76 0.19 2.1 (1.5-3.1)
(pN2 vs pN1)
Histological type 0.21
Tumour necrosis 0.50
Mitotic count 0.79
Corrected survival
Histological grade < 0.001 0.55 0.10 1.7 (1.4-2.1)
(G3 vs G2 vs Gl)
Primary tumour size < 0.001 0.58 0.10 1.8 (1.5-2.2)
(pT3-4 vs pT2 vs pTl)
Axillary nodal status 0.001 0.70 0.20 2.0 (1.4-3.0)
(pN2 vs pN1)
Histological type 0.12
Tumour necrosis 0.54
Mitotic count 0.55
Table 4 Survival by the decade of diagnosis
Time period n Survival corrected for intercurrent deaths
5-year 10-year 15-year 20-year 30-year
(%) (%) (%) (%) (%)
1945-59 102 28 16 13 13 12
1960-69 96 52 36 30 26 24
1970-79 141 55 45 34 30 -
with TINIMO disease might not have a recurrence within a nearly
20-year follow-up period. The long-term survival rate of 24%
found in the present series treated with locoregional therapy in
pN1-disease may be a conservative estimate regarding many
women with pN1 breast cancerdiagnosed at present, because more
cancers with a small primary tumour and minimal axillary nodal
involvement are now being diagnosed.
Although several conventional prognostic factors that correlated
strongly with survival could be identified (Tables 2 and 3), none of
the factors could identify a subset of patients with particularly
favourable survival. Hence, adjuvant systemic therapy should
probably be recommended to all patients with pN+ disease,
because there is currently no reliable way to identify patients who
might be cured without adjuvant therapy. However, the newer
prognostic factors should be tested for this purpose.
In a randomized Danish study consisting of more than 1700
premenopausal patients with stage II or III breast cancer radio-
therapy to the chest wall and the regional lymph nodes was found
not only to reduce the frequency of locoregional relapses from
32% to 9%, but to increase significantly both disease-free and
overall survival compared with patients who were treated with
mastectomy and adjuvant chemotherapy alone (Overgaard et al,
1997). Similar results were also obtained in a randomized
Canadian study (Ragaz et al, 1997). Both of these studies suggest
that recurrent locoregional cancer may give rise to distant metas-
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tases in addition to the primary cancer, and that irradiation of the
subclinical locoregional lymph node and chest wall metastases
improves survival. These data also support the hypothesis that
node-positive breast cancer has not always given rise to distant
metastases, and that careful management of the regional lymph
node regions is beneficial. Coupled with the present data, data
from these randomized trials suggest that adequate locoregional
therapy can cure many women with node-positive breast cancer.
We found better survival among the patients diagnosed in the
1960s and 1970s compared with those diagnosed earlier. The
reasons for this remain speculative, but improved survival with
time might in part be explained by reduction in breast cancer size
and less extensive axillary nodal involvement in the 1970s
compared with the 1940s and 1950s. However, improvements in
surgical and radiotherapy techniques may also play a role. Modern
locoregional radiotherapy improves survival in node-positive
breast cancer, and orthovoltage and cobalt therapy used in the city
in the 1940s to 1960s may have been inferior to radiotherapy given
with linear accelerators in the 1970s. The rate of axillary nodal
dissection did not increase consistently during the study period in
the city (83%, 77% and 90% ofpatients had axillary nodal dissec-
tion in 1945-59, 1960-69 and 1970-79 respectively). Breast
cancer, per se, might also have become less aggressive with time,
but we consider this unlikely. When a few biological and histo-
logical prognostic factors were compared between breast cancers
diagnosed in the city in the 1980s and those diagnosed in the 1940s
to 1960s adjusting for the generally smaller size of the cancers
diagnosed in the 1980s, little change in the malignancy grade with
time could be found (Joensuu and Toikkanen, 1991).
In conclusion, the present results suggest that a subgroup of
women with axillary nodal metastases from ipsilateral breast
cancer are permanently cured by locoregional therapy alone.
Therefore, axillary nodal involvement is not a conclusive sign of
disseminated disease. Furthermore, the time trends in the study
cohort suggest that the long-term survival rate of 24% among
patients with pN1 disease and treated with locoregional therapy is
a conservative estimate. The present results combined with those
of recently published randomized trials suggest that careful loco-
regional treatment is mandatory in the care of node-positive breast
cancer in addition to systemic therapy.
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